The number of new graduates hired for sales rep roles increased in FY2025 after declining for five consecutive years, a…
REGULATORY
Japan to Apply Leqembi’s General Pricing Rules for Similar AD Therapies
The Central Social Insurance Medical Council (Chuikyo) on November 13 adopted a broad policy for the pricing of expensive Alzheimer’s disease (AD) drugs including Eli Lilly’s Kisunla (donanemab), which was given the nod on the day for listing later this…
To read the full story
Related Article
- Kisunla Gets Reimbursement Listing with Daily NHI Price of 8,560 Yen
November 14, 2024
- Kisunla to Follow Same Rules as Leqembi in Pricing and Post-Launch Review
October 10, 2024
- Kisunla Subject to Prior Pricing Review as It Follows Leqembi’s Footsteps
September 26, 2024
- Japan Approves Lilly’s Kisunla, Eisai’s ALS Med, Gilead’s Trodelvy, and Lots More
September 25, 2024
- Leqembi to Cost 2.98 Million Yen per Year, Re-Pricing Might Be Triggered on Patient Upswing
December 14, 2023
- Chuikyo Agrees to Adopt Normal Rules to Price, Re-Price Leqembi
November 16, 2023
- Leqembi Subject to Cost Control Rule for Potential Big Sellers, MHLW Still Set to Meet Listing Deadline
September 26, 2023
REGULATORY
- LDP Project Team Eyes Coverage Discussions for Drug Use in Pre-Symptomatic Stage
May 20, 2025
- New Stelara Biosimilars Earn May Listing, Eylea Follow-On Takes Pass Again
May 20, 2025
- Japan Approves Moderna RSV Vaccine, GSK’s ADC, and More
May 20, 2025
- Ex-Lawmakers’ Club Proposes CEA Overhaul, GDP-Linked Drug Spending
May 16, 2025
- Ex-PM Kishida Stresses Need to Bolster Innovation in Japan: Tokyo Speech
May 16, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…